EDAP TMS S.A. (EDAP) Reports Q3 EPS of EUR0.19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro boost AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
EDAP Reports Third Quarter 2015 Financial Results and Operational Update
November 18, 2015 5:45 PM ESTObtained FDA clearance for Ablatherm® HIFU in November Received first four U.S. orders for Ablatherm Record nine-month net sales of 20.5 million HIFU treatment-driven revenue increased 41% year-over-year Strong backlog for both lithotripsy and HIFU divisions entering Q4 First Focal One® Device sold in South America
LYON, France, Nov. 18, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced financial results for the third quarter ended September 30, 2015 and provided an update on recent strategic and operational highlights.
Marc... More



